Certuity LLC Sells 15,351 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Certuity LLC lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 11.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,281 shares of the biopharmaceutical company’s stock after selling 15,351 shares during the period. Certuity LLC’s holdings in Bristol Myers Squibb were worth $7,275,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Ameriprise Financial Inc. increased its holdings in Bristol Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares during the period. GQG Partners LLC increased its holdings in Bristol Myers Squibb by 22,647.6% during the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock worth $733,310,000 after acquiring an additional 11,970,598 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Bristol Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company’s stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the period. Nuveen LLC bought a new stake in Bristol Myers Squibb during the 1st quarter worth approximately $624,369,000. Finally, Northern Trust Corp increased its holdings in Bristol Myers Squibb by 16.2% during the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company’s stock worth $1,394,677,000 after acquiring an additional 3,431,248 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 2.7%

Shares of BMY opened at $47.82 on Thursday. The stock has a market capitalization of $97.33 billion, a P/E ratio of 19.28, a PEG ratio of 2.38 and a beta of 0.36. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The firm has a fifty day simple moving average of $47.23 and a two-hundred day simple moving average of $51.66. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.07 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.2%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Ratings Changes

A number of analysts recently weighed in on BMY shares. Citigroup decreased their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target on the stock. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.